N/A N=48 Clinical Evaluation of the Levita Robotic Platform
Bariatric Surgery Candidate · Cholelithiases · Other Disease
Primary: Adverse Events Related to the Device — 3 Adverse events related to device
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Pharmacy-based Pre-exposure Prophylaxis
Human Immunodeficiency Virus
Primary: Number of Participants Continuing PrEP — 2 Participants
N/A N=122 Building Resiliency in Patients Admitted to the Neuroscience Intensive Care Unit and Their Caregivers
Acute Brain Injuries
Primary: Feasibility of Recruitment (Ability to Recruit Dyads) — 122; 40; 4 Participants
Phase 4 N=2 Effect of Tetrabenazine on Stroop Interference in HD
Huntington Disease
Primary: Change in Stroop Interference Score — -1.97; -1 score on a scale
Phase 1 N=108 Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant
Chronic Obstructive Pulmonary Disease
Primary: Maximum Observed Plasma (Peak) Drug Concentration (Cmax ) — 1078; 1111; 1045; 14.31 picograms per milliliter (pg/mL)
N/A N=1,048 A Depression and Opioid Pragmatic Trial in Pharmacogenetics (Chronic Pain Trial)
Chronic Pain
Primary: Change in Pain Intensity — -0.7; -0.8 score on a scale — p=0.5913
N/A N=28 Therapist-Guided Smartphone-Delivered CBT for MDD
Major Depressive Disorder
Primary: Drop-Out Rates — 2; 26 Participants
N/A N=20 Fractionated Stereotactic Radiosurgery for Large Brain Metastases
Large Brain Mets
Primary: Number of Patients Experiencing DLT — 0; 0; 0; 0 participants
N/A N=121 Emergence Agitation Between Dexmedetomidine and Sevoflurane Anesthesia
Emergence Delirium
Primary: Emergence Agitation — 3.9; 2.5 Score on a scale — p=0.001
Phase 2 N=23 An Open-Label Multiple Dose Study of RZ358 in Patients With Congenital Hyperinsulinism
Congenital Hyperinsulinism
Primary: Median of Average Daily Percent Time Within a Glucose Target Range of 70-180 mg/dL (3.9-10 mmol/L) by CGM at Baseline (BL) and End of Treatment (EOT) — 81.7; 72.9; 83.4…
N/A N=668 Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project
Breast Cancer · Ovarian Cancer
Primary: Medically Verified Cancer Genetic Risk Assessment Uptake at 6 Months — 5; 6; 32 Participants — p=<.0001
N/A N=43 Clinical Utility of Handheld Hydrogen Breathalyzer in Identification of Food Sensitivities (AIRE Study)
SIBO · Small Bowel Bacterial Overgrowth Syndrome
Primary: Hydrogen Content in Parts Per Million (Ppm) — 3.5 ppm
Phase 4 N=87 The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Hepatitis C, Chronic
Primary: Sustained Virologic Response at 12-weeks (SVR-12) — 58; 58 Participants
N/A N=22 SPM Regulation by Fish Oil Supplements in Healthy Volunteers
Healthy Volunteers
Primary: Increase in the Average Peripheral Blood SPM Levels — 56.49; 56.91; 108.8; 139.7 pg/mL
Phase 3 N=94 Effect & Safety of Inhaled Isoflurane vs IV Midazolam for Sedation in Mechanically Ventilated Children 3-17 Years Old
Sedation
Primary: Percentage of Time of Adequately Maintained Sedation Depth up to 48 Hours (± 6 Hours) — 62.37; 68.94 Percentage of time